U.S. markets open in 26 minutes

Blueprint Medicines Corporation (BPMC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
93.02-5.77 (-5.84%)
At close: 4:00PM EST

93.02 0.00 (0.00%)
Pre-Market: 8:00AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close98.79
Bid0.00 x 1800
Ask0.00 x 1400
Day's Range92.52 - 99.16
52 Week Range43.29 - 125.61
Avg. Volume477,786
Market Cap5.391B
Beta (5Y Monthly)0.73
PE Ratio (TTM)16.64
EPS (TTM)5.59
Earnings DateMay 04, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est117.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
    PR Newswire

    Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis

    Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of advanced systemic mastocytosis (SM). Validation of the application confirms that the submission is sufficiently complete to begin the formal review process. The European Commission has granted orphan medicinal product designation to AYVAKYT for the treatment of mastocytosis.

  • 15 Fastest Growing Biotech Companies in the US
    Insider Monkey

    15 Fastest Growing Biotech Companies in the US

    In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]

  • Benzinga

    Recap: Blueprint Medicines Q4 Earnings

    Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62). Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000. Looking Ahead Blueprint Medicines hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 17, 2021 View more earnings on BPMC Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy Recent Stock Performance Company's 52-week high was at $125.61 52-week low: $43.29 Price action over last quarter: down 8.88% Company Description Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 17, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.